Alexandra Gerlach, Content Producer

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Statins and non-statin cholesterol-lowering agents show potential in reducing the risk of liver cancer.

The findings may lead to the development of diagnostic and therapeutic targets to prevent worsening disease in patients.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

The findings highlight the potential for developing more efficacious combination treatments for patients with glioblastoma.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Afamitresgene autoleucel (afami-cel) is a novel cell therapy for the treatment of patients with synovial sarcoma.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

The findings provide guidance for clinicians and patients when navigating therapeutic options to establish treatment plans.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

The decision is based on positive results from the PERSEUS trial.

The approval streamlines treatment administration to eliminate compounding steps, reduce preparation time, and enhance safety for clinicians.

Pharmacists can help patients with polycystic ovary syndrome safely incorporate complementary supplements, such as cinnamon, into their treatment plan.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

The blood test offers patients advanced screening methods capable of detecting colorectal cancer in its earlier stages.

Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.

Study finds traces of “epigenetic scars” on the immune cells of patients who recovered from chronic hepatitis C infection.

New strategies can improve cholesterol management in patients with ASCVD.

The decision offers patients with difficulty swallowing their medication expanded options for treatment administration.

The decision expands the use of incobotulinumtoxinA beyond treatment of frown lines.

β2-microglobulin may be an effective indicator of coagulation dysfunction in patients with newly diagnosed multiple myeloma (NDMM).

The findings showed that pharmacist-led interventions resulted in the greatest systolic blood pressure reductions.

Acetylcholine deficit observed in patients with anorexia nervosa suggest potential targeted treatment options.

Radiotherapy may have applications beyond symptomatic relief when used in combination with immunotherapy.

Use of semaglutide injections may be linked to an increased risk of blindness in patients with diabetes.